Abstract
Purpose Longitudinal data on the experience and perpetration of intimate partner violence (IPV) among gay, bisexual, and other men who have sex with men (GBM) is limited. We estimated the prevalence of past six-month (P6M) physical and/or sexual IPV (hereafter IPV) experience and perpetration, identified their determinants, and assessed temporal trends, including the impact of the COVID-19 pandemic.
Methods We used data from the Engage Cohort Study (2017-2022) of GBM recruited using respondent-driven sampling in Montréal, Toronto, and Vancouver. Adjusted prevalence ratios (aPR) for determinants and self-reported P6M IPV were estimated using generalized estimating equations, accounting for attrition (inverse probability of censoring weights) and relevant covariates. Longitudinal trends of IPV were also assessed.
Results Between 2017-2022, 1,455 partnered GBM (median age 32 years, 82% gay, and 71% white) had at least one follow-up visit. Baseline proportions were 31% for lifetime IPV experience and 17% for lifetime perpetration. During follow-up, P6M IPV experience was more common (6%, 95%CI: 5-7%) than perpetration (4%, 95%CI: 3-5%). Factors associated with P6M IPV experience include prior IPV experience (aPR=2.79, 95%CI: 1.83-4.27), less education (aPR=2.08, 95%CI: 1.14-3.79), and substance use (injection aPR=5.68, 95%CI: 2.92-11.54, non-injection aPR=1.70, 95%CI: 1.05-2.76). Similar factors were associated with IPV perpetration. IPV was stable over time; periods of COVID-19 restrictions were not associated with IPV changes in this cohort.
Conclusion Prevalence of IPV was high among GBM. Determinants related to marginalization are associated with an increased risk of IPV. Interventions should address these determinants to reduce IPV and improve health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Engage has been/is funded by the Canadian Institutes for Health Research (CIHR, #TE2-138299, #PH2-409374, FDN-143342, PJT-153139, #VR5-172677), the CIHR Canadian HIV/AIDS Trials Network (#CTN300, #CTN300-2), the Canadian Association for HIV/AIDS Research (CANFAR, #Engage), the Ontario HIV Treatment Network (OHTN, #1051), the Public Health Agency of Canada (#4500370314), Canadian Blood Services (#MSM2017LP-OD), and the COVID Immunity Task Force (CITF). S.J. is supported by the CIHR 2SLGBTQ+ Health Hub fellowship and received support from the McGill Faculty of Family Medicine Internal Studentship during his master's thesis. S.S.S. was supported by CTN and CIHR postdoctoral fellowships. D.G. is supported by a Canada Research Chair (Tier 2) in Sexual and Gender Minority Health. T.A.H. was supported by a Chair in Gay and Bisexual Men's Health from the OHTN. M.M-G.'s research program is funded by a Canada Research Chair (Tier 2) in Population Health Modeling.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Research Institute of the McGill University Health Centre, Toronto Metropolitan University, St. Michael's Hospital, University of Toronto (Health Sciences), University of British Columbia, University of Victoria, and Simon Fraser University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Potential conflicts of interest: All authors report no potential conflicts.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.